Investigating how specific mutations in the LIS1 gene affect dynein function in neurological diseases.

Using LIS1 missense mutations to probe dynein regulatory mechanisms

NIH-funded research University of South Carolina at Columbia · NIH-10544530

This study is looking at how changes in the LIS1 gene might affect the severity of neurological diseases like Alzheimer's and ALS, helping us understand why some patients with these gene changes experience different symptoms.

Quick facts

Grant typeR21 grant
Study typeNIH-funded research
Funding institutionUniversity of South Carolina at Columbia NIH-funded
Lab location1 site (Columbia, United States)
Project IDNIH-10544530 on NIH RePORTER

What this research studies

This research focuses on understanding how mutations in the LIS1 gene, which regulates the dynein motor protein, can influence the severity of neurological diseases such as Alzheimer's and ALS. By examining specific missense mutations, the study aims to uncover how these changes affect dynein interactions and cellular processes in the nervous system. Patients with these mutations may have varying disease outcomes, and the research will explore these differences to better understand the underlying mechanisms. The approach includes biological assays and genetic analysis to assess the impact of these mutations.

Who could benefit from this research

Good fit: Ideal candidates for this research include individuals diagnosed with Alzheimer's disease, ALS, or those with known LIS1 mutations.

Not a fit: Patients without any genetic mutations related to LIS1 or those with unrelated neurological conditions may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to improved understanding and potentially new therapeutic strategies for patients with Alzheimer's disease and ALS.

How similar studies have performed: Previous research has shown that understanding genetic mutations in neurological diseases can lead to significant advancements in treatment, indicating potential success for this approach.

Where this research is happening

Columbia, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions Alzheimer disease dementiaAlzheimer syndromeAlzheimer's Disease
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.